Samsung Bioepis and Organon (OGN) announced that the FDA has designated the Hadlima high- and low-concentration autoinjectors and high-concentration prefilled syringe as interchangeable biosimilars to Humira. These interchangeability designations follow the interchangeability designation received for the Hadlima low-concentration prefilled syringe and single-dose vial in June 2024.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OGN: